Manuel Carrondo,
Professor,
Universidade Nova de Lisboa
Chemical Engineer, 1971, Univ. Porto; Master of Sciences (1975) and Philosophy Doctor (1979) Environmental Engineering, Imperial College of Science and Technology, U. London; Habilitation, Chemical Engineering (1991), Univ. Nova de Lisboa. Full Professor, Chemical and Biochemical Engineering, Faculty of Sciences and Technology, Univ. Nova de Lisboa. Founder and earlier president (currently CEO) of IBET – Institute for Experimental and Technological Biology (www.ibet.pt), founder and board member of the Portuguese Academy of Engineering (1998-2001) and board member of the Euro CASE (Council on Applied Science and Engineering) (1998-2001), chairman of the European Society of Animal Cell Technology (ESACT) (1997-2001) and of Medical Biotechnology Section of the European Federation of Biotechnology (EFB) (1999-2001), member and Vice- Chairman of the External Advisory Group “Cell Factory” (Research Directorate General, European Commission) (1998-2002), member of the Advisory Board of Max – Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Amgen Bioprocessing Center, KGI, Claremont, California, CEVEC Pharmaceuticals, Köln, PBS Biotech, California and CNIC - Spanish National Center for Cardiovascular Research Carlos III, Spain. Founder and CSO of GenIBET Biopharmaceuticals (2006-2008) (www.genibet.eu). Meeting Chairman of the ESACT 14th Meeting “Animal Cell Technology: From Vaccines to Genetic Medicine”, Vilamoura, May 1996 and of the “3rd Recombinant Protein Production Meeting: A comparative view on host physiology"", Tavira-Algarve (Portugal), November 2004. Visiting Professor at Carnegie-Mellon Univ. (1981), Massachusetts Institute of Technology - MIT (1988), Geselchaft für Biotechnologische Forschung (1989 and 1993). Supervised twenty-eight Ph.D. students (thesis defended) and published over one hundred ninety papers in refereed international journals; Associate-Editor of Journal of Biotechnology, member of the editorial board of Biotechnology and Bioengineering, Current Gene Therapy and Biotechnology Letters; referee of Biotechnology Progress, Cytotechnology, Applied Microbiology and Biotechnology, Enzyme and Microbial Biotechnology. Key areas of research interest: Animal Cell Technology and its application for human and animal health (http://tca.itqb.unl.pt). Therapeutic and diagnostic recombinant proteins, including fusion proteins; virus like particles and pseudo viruses as vaccination agents and viruses (retro-, adeno-, lenti-) as deliverables for gene therapy; cell therapies and stem cells. cGMP pilot plant scale-up and production development of biopharmaceuticals.
|
|